Ashlee Brunaugh

Dr. Ashlee Brunaugh

orcid

Research Focus & Metrics

Academic Career Length

11Years (2016-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
13 February 2017 in The AAPS Journal
Verified
Journal Article
Closed access
PDF file
JMJavier Morales
Javier Morales
KFKristin R. Fathe
Kristin R. Fathe
ABAshlee Brunaugh
Ashlee Brunaugh
SFSilvia Ferrati
Silvia Ferrati
SLSong Li
Song Li
Hugh D.C. SmythHugh D.C. Smyth
Hugh D.C. Smyth

11 February 2021 in PLOS ONE
Verified
Journal Article
Open access
PDF file
ABAshlee Brunaugh
Ashlee Brunaugh
HSHyojong Seo
Hyojong Seo
ZWZachary Warnken
Zachary Warnken
LDLi Ding
Li Ding
SSSang Heui Seo
Sang Heui Seo
Hugh D.C. SmythHugh D.C. Smyth
Hugh D.C. Smyth
Niclosamide (NIC) has demonstrated promising in vitro antiviral efficacy against SARS-CoV-2, the causative agent of the COVID-19 pandemic. Though NIC is already FDA-approved, administration of the currently available oral formulation results in systemic drug levels that are too low for the inhibition of SARS-CoV-2. We hypothesized that the co-formulation of NIC with an endogenous protein, human lysozyme (hLYS), could enable the direct aerosol delivery of the drug to the respiratory tract as an alternative to oral delivery, thereby effectively treating COVID-19 by targeting the primary site of SARS-CoV-2 acquisition and spread. To test this hypothesis, we engineered and optimized composite particles containing NIC and hLYS suitable for delivery to the upper and lower airways via dry powder inhaler, nebulizer, and nasal spray. The novel formulation demonstrates potent in vitro and in vivo activity against two coronavirus strains, MERS-CoV and SARS-CoV-2, and may offer protection against methicillin-resistance staphylococcus aureus pneumonia and inflammatory lung damage occurring secondary to SARS-CoV-2 infections. The suitability of the formulation for all stages of the disease and low-cost development approach will ensure rapid clinical development and wide-spread utilization.

1 August 2018 in International Journal of Pharmaceutics
Verified
Journal Article
Closed access
ABAshlee Brunaugh
Ashlee Brunaugh
Hugh D.C. SmythHugh D.C. Smyth
Hugh D.C. Smyth

26 August 2019 in Molecular Pharmaceutics
Verified
Journal Article
Closed access
ABAshlee Brunaugh
Ashlee Brunaugh
TWTian Wu
Tian Wu
SKSekhar R. Kanapuram
Sekhar R. Kanapuram
Hugh D.C. SmythHugh D.C. Smyth
Hugh D.C. Smyth

19 October 2017 in Molecular Pharmaceutics
Verified
Journal Article
Closed access
ABAshlee Brunaugh
Ashlee Brunaugh
SJSyed Umer Jan
Syed Umer Jan
SFSilvia Ferrati
Silvia Ferrati
Hugh D.C. SmythHugh D.C. Smyth
Hugh D.C. Smyth

3 August 2021 in Expert Opinion on Drug Delivery
Verified
Journal Article
Closed access
ABAshlee Brunaugh
Ashlee Brunaugh
SSShivam Sharma
Shivam Sharma
Hugh D.C. SmythHugh D.C. Smyth
Hugh D.C. Smyth
Introduction Respiratory infections are a major cause of morbidity and mortality. As an alternative to systemic drug administration, inhaled drug delivery can produce high drug concentrations in the lung tissue to overcome resistant bacteria. The development of inhaled fixed-dose combination powders (I-FDCs) is promising next step in this field, as it would enable simultaneous drug-drug or drug-adjuvant delivery at the site of infection, thereby promoting synergistic activity and improving patient compliance. Areas covered This review covers the clinical and pharmaceutical rationales for the development of I-FDCs for the treatment of respiratory infections, relevant technologies for particle and powder generation, and obstacles which must be addressed to achieve regulatory approval. Expert opinion I-FDCs have been widely successful in the treatment of asthma and chronic obstructive pulmonary disease; however, application of I-FDCs towards the treatment of respiratory infections carries additional challenges related to the high dose requirements and physicochemical characteristics of anti-infective drugs. At present, co-spray drying is an especially promising approach for the development of composite fixed-dose anti-infective particles for inhalation. Though the majority of fixed-dose research has thus far focused on the combination of multiple antibiotics, future work may shift to the additional inclusion of immunomodulatory agents or repurposed non-antibiotics.